Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberWO2005092277 A1
Publication typeApplication
Application numberPCT/EP2005/002879
Publication date6 Oct 2005
Filing date16 Mar 2005
Priority date25 Mar 2004
Publication numberPCT/2005/2879, PCT/EP/2005/002879, PCT/EP/2005/02879, PCT/EP/5/002879, PCT/EP/5/02879, PCT/EP2005/002879, PCT/EP2005/02879, PCT/EP2005002879, PCT/EP200502879, PCT/EP5/002879, PCT/EP5/02879, PCT/EP5002879, PCT/EP502879, WO 2005/092277 A1, WO 2005092277 A1, WO 2005092277A1, WO-A1-2005092277, WO2005/092277A1, WO2005092277 A1, WO2005092277A1
InventorsAlison Katharine Green, Ilaria Faravelli
ApplicantUnilever N.V., Unilever Plc, Hindustan Lever Limited
Export CitationBiBTeX, EndNote, RefMan
External Links: Patentscope, Espacenet
Oral composition
WO 2005092277 A1
Abstract
An oral composition comprising zinc citrate, a betaine derivative and an anionic surfactant, characterised in that the composition comprises the betaine derivative and the anionic surfactant in a weight ratio of from 0.5:1 to 2:1.
Claims  (OCR text may contain errors)
1. An oral composition comprising zinc citrate, a betaine surfactant and an anionic surfactant, characterised in that the composition comprises the betaine derivative and the anionic surfactant in a weight ratio of from 0.5:1 to 2:1.
2. An oral composition according to claim 1 wherein the betaine surfactant is cocoamidopropyl betaine.
3. An oral composition according to any preceding claim wherein the anionic surfactant is sodium lauryl sulphate.
4. An oral composition according to ^any preceding claim wherein the composition comprises from 0.5 to 1.3% by weight anionic surfactant.
5. An oral composition according to any preceding claim wherein the composition comprises from 0.5 to 1.3% by weight betaine surfactant.
Description  (OCR text may contain errors)

ORAL COMPOSITION

The present invention relates to an oral composition according to the preamble of claim 1.

The object of the present invention is to provide an oral composition which improves the delivery of sparingly soluble zinc citrate from an oral composition comprising an anionic surfactant.

WO02/026203 (Henkel) discloses an oral composition comprising cocoacylamidopropyl betaine and sodium lauryl sulphate. The composition also comprises zinc sulphate, a water soluble zinc salt.

Accordingly, the present invention provides an oral composition according to claim 1.

Preferably, the composition comprises the betaine derivative and the anionic surfactant in a weight ratio of from 0.95:1 to 1.05:1.

Preferably, the oral care composition according to the invention comprises from 0.001 to 5% by weight zinc citrate, more preferably from 0.5 to 3.0% by weight.

Suitable anionic surfactants are, for example, sodium alkyl sulfates containing 12 to 18 carbon atoms in the alkyl group. Other suitable anionic surfactants are alkali metal salts, preferably sodium salts of alkyl polyglycol ether sulfate containing 12 to 16 carbon atoms in the linear alkyl group and 2 to 6 glycol ether groups in the molecule, of linear alkane (C 12-18) sulfonate, • of sulfosuccinic acid onoalkyl (C 12-18 ) esters, of .suJLfated fatty acid onoglycerides, sulfated fatty acicTalkanolamides, sulfoacetic acid alkyl (C 12-16' ).* esters, acyl sarcosines, acyl taurides and acyl isothionates containing 8 to 18 carbon atoms in the acyl group.

Suitable betaine surfactants include cocoalkyl betaine or cocoamidopropyl betaine.

Preferably the antimicrobial agent is present in an amount of from 0.01 to 5% by weight of the composition, more preferably from 0.5 to 3% by weight..

The oral composition according to the invention comprise further ingredients which are common in the art, such as:

antimicrobial agents, e.g. Triclosan, chlorhexidine, sanguinarine extract, metronidazole, quaternary ammonium compounds, such as cetylpyridinium chloride; bis-guanides, such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; halogenated bisphenolic compounds, such as 2,2' methylenebis- (4-chloro-6-bromophenol) , and the alkyl parabens such as n-octyl paraben and analogues thereof;

anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc.; anti-caries agents such as sodium- and stannous fluoride, aminefluorides, sodium monofluorophosphate, sodium trimeta phosphate and casein;

plaque buffers such as urea, calcium lactate, calcium glycerophosphate and strontium polyacrylates;

vitamins such as Vitamins A, C and E;

plant extracts;

desensitising agents, e.g. potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate and strontium salts;

anti-calculus agents, e.g. alkali-metal pyrophosphates, hypophosphite-containing polymers, organic phosphonates and phosphocitrates etc.;

biomolecules, e.g. bacteriocins, antibodies, enzymes, etc.; flavours, e.g. peppermint and spearmint oils;

proteinaceous materials such as collagen;

preservatives;

opacifying agents;

colouring agents;

pH-adjusting agents; sweetening agents;

pharmaceutically acceptable carriers, e.g. starch, sucrose, water or water/alcohol systems etc.;

surfactants, such as anionic, nonionic, cationic and zwitterionic or amphoteric surfactants;

particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, calcium pyrophosphates, hydroxyapatites, tri etaphosphates, insoluble hexametaphosphates and so on, including agglomerated particulate abrasive materials, usually in amounts between 3 and 60% by weight of the oral care composition.

polymeric compounds which can enhance" the delivery of active ingredients such as antimicrobial agents can also be included;

buffers and salts to buffer the pH and ionic strength of the oral care composition; and

other optional ingredients that may be included are e.g. bleaching agents such as peroxy compounds e.g. potassium peroxydiphosphate, effervescing systems such as sodium bicarbonate/citric acid systems, colour change systems, and so on.

Liposomes may also be used to improve delivery or stability of active ingredients. The oral compositions may be in any form common in the art, e.g. toothpaste, gel, mousse, gum, cream, etc. and may also be formulated into systems for use in dual-compartment type dispensers.

The toothpaste according to the invention is made by standard processes. An example of an 'oral composition according to the invention is found in the Example. It is made using processes known to the person skilled in the art.

EXAMPLE

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
WO1995001173A1 *29 Jun 199412 Jan 1995Unilever N.V.Amphoteric surfactant for the treatment of aphthous ulcers
WO1996029049A1 *20 Feb 199626 Sep 1996Unilever PlcLiquid cleansing formulations
WO2002026203A2 *18 Sep 20014 Apr 2002Henkel Kommanditgesellschaft Auf AktienDental cleaning agents
DE10047760A1 *27 Sep 200011 Apr 2002Henkel KgaaZahnreinigungsmittel
US6169118 *4 Nov 19992 Jan 2001Block Drug Company, Inc.Flavor blend for masking unpleasant taste of zinc compounds
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO2007076444A3 *21 Dec 200616 Aug 2007Colgate Palmolive CoImproved oral compositions comprising zinc citrate and/or tocopherol agents
Classifications
International ClassificationA61K8/44, A61K8/365, A61K8/46, A61K8/27, A61Q11/00
Cooperative ClassificationA61Q11/00, A61K8/463, A61K8/442, A61K8/365
European ClassificationA61K8/44D, A61K8/365, A61Q11/00, A61K8/46C
Legal Events
DateCodeEventDescription
6 Oct 2005AKDesignated states
Kind code of ref document: A1
Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
6 Oct 2005ALDesignated countries for regional patents
Kind code of ref document: A1
Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
30 Nov 2005121Ep: the epo has been informed by wipo that ep was designated in this application
26 Sep 2006NENPNon-entry into the national phase in:
Ref country code: DE
26 Sep 2006WWWWipo information: withdrawn in national office
Country of ref document: DE
25 Apr 2007122Ep: pct application non-entry in european phase